Overview
This joint resolution exercises Congress's authority under the Congressional Review Act to disapprove and nullify a rule issued by the Bureau of Consumer Financial Protection. The targeted rule withdraws previous regulations concerning debt collection practices, specifically those addressing deceptive and unfair collection of medical debt under Regulation F. By invoking congressional disapproval, this resolution seeks to preserve the consumer protections that were established in the original medical debt collection rule and prevent the Bureau from eliminating those safeguards. The resolution represents a legislative check on agency rulemaking authority, ensuring that regulatory changes affecting medical debt collection practices receive congressional scrutiny and approval.
Core Provisions
The resolution contains a single operative provision that formally disapproves the Bureau of Consumer Financial Protection's rule withdrawing protections related to medical debt collection practices. The disapproved rule was published in two Federal Register notices, first on October 4, 2024, and subsequently on May 12, 2025. Upon enactment, the resolution renders the Bureau's withdrawal rule void and without legal effect, meaning the underlying consumer protections for medical debt collection remain in force. The resolution does not create new programs, authorize funding, or establish implementation timelines beyond the immediate nullification of the disapproved rule upon passage.
Key Points
- Disapproves CFPB rule published at 89 Fed. Reg. 80715 (October 4, 2024)
- Disapproves CFPB rule published at 90 Fed. Reg. 20084 (May 12, 2025)
- Renders the withdrawal rule without force or effect
- Preserves original Regulation F protections for medical debt collection
Legal References
- Chapter 8 of title 5, United States Code (Congressional Review Act)
- 89 Fed. Reg. 80715 (October 4, 2024)
- 90 Fed. Reg. 20084 (May 12, 2025)
- Regulation F (Debt Collection Practices)
Implementation
Implementation of this resolution is immediate and self-executing upon enactment. The Bureau of Consumer Financial Protection bears primary responsibility for compliance, as it must cease enforcement of the disapproved withdrawal rule and continue applying the original medical debt collection protections under Regulation F. No additional funding mechanisms are required, as the resolution simply maintains the status quo ante by preventing the Bureau's regulatory rollback. The resolution does not establish reporting requirements or create new compliance measures beyond the Bureau's existing obligations under the preserved regulations. Enforcement continues through the Bureau's standard regulatory authority, with the original Regulation F provisions remaining operative for debt collectors subject to CFPB jurisdiction.
Impact
The primary beneficiaries of this resolution are consumers with medical debt who retain protections against deceptive and unfair collection practices that would have been eliminated by the Bureau's withdrawal rule. Debt collectors and creditors face continued compliance obligations under the original Regulation F standards for medical debt collection, maintaining existing operational requirements rather than creating new burdens. The resolution imposes no direct federal costs, as it preserves existing regulatory infrastructure without establishing new programs or administrative requirements. The expected outcome is sustained consumer protection in medical debt collection contexts, preventing potential increases in abusive collection practices that might have occurred following the rule's withdrawal. No sunset provisions apply, as the resolution's effect is permanent nullification of the specific withdrawal rule.
Key Points
- Consumers with medical debt retain protections against unfair collection practices
- Debt collectors must continue compliance with Regulation F medical debt provisions
- No new federal expenditures required
- Maintains existing CFPB administrative framework
Legal Framework
The resolution operates under the Congressional Review Act, codified in Chapter 8 of title 5, United States Code, which grants Congress authority to review and disapprove agency rules through expedited legislative procedures. This statutory framework provides the constitutional basis for congressional oversight of executive branch rulemaking, rooted in Article I legislative powers and the separation of powers doctrine. The resolution's effect is to maintain federal preemption in the debt collection field as established under the original Regulation F, preventing the Bureau from creating a regulatory vacuum that might otherwise allow inconsistent state-level approaches to medical debt collection. The Congressional Review Act includes provisions limiting judicial review, though courts retain jurisdiction to determine whether the resolution was validly enacted and whether subsequent agency actions constitute impermissible attempts to reissue substantially similar rules.
Legal References
- Chapter 8 of title 5, United States Code (Congressional Review Act)
- Article I, U.S. Constitution (Legislative Powers)
- Fair Debt Collection Practices Act (15 U.S.C. § 1692 et seq.)
- Consumer Financial Protection Act (12 U.S.C. § 5481 et seq.)
Critical Issues
The resolution raises significant policy tensions between congressional oversight and agency expertise in consumer financial protection. Implementation challenges center on the Congressional Review Act's prohibition against the Bureau issuing substantially similar rules in the future, potentially constraining the agency's ability to adapt medical debt collection regulations to evolving market conditions or enforcement experience. The resolution reflects fundamental disagreement over the appropriate level of consumer protection in medical debt collection, with supporters arguing that the Bureau's withdrawal would have exposed vulnerable consumers to predatory practices, while potential opponents might contend that existing protections impose excessive compliance costs on legitimate debt collection activities. The lack of cost-benefit analysis in the resolution itself leaves uncertain the economic implications for both consumers and the debt collection industry. Unintended consequences may include regulatory ossification if the Bureau cannot refine medical debt collection rules based on implementation experience, or potential litigation over whether future Bureau actions constitute prohibited attempts to reissue the disapproved withdrawal rule.
Key Points
- Constrains CFPB's future rulemaking flexibility on medical debt collection
- Reflects policy disagreement over appropriate consumer protection levels
- May prevent adaptive regulation based on market developments
- Potential litigation over scope of 'substantially similar' rule prohibition
- Economic impact on debt collection industry compliance costs uncertain